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Introduction
Genome Wide Association Study (GWAS) variants on
chromosome 15q25 and 5p15 and genetic polymorphisms
on the vascular endothelial growth factor (VEGF) gene
showed that they may contribute to lung carcinogenesis.
Therefore, this study was performed in order to assess the
role of GWAS, and VEGF variants in non-small-cell lung
cancer (NSCLC) prognosis.
Materials and methods
Prospective study from February 2010 to April 2011.
Median follow up was 12 months. NSCLC patient’s geno-
typing was performed using the Sequenom® MassARRAY
platform. Kaplan-Meier curve was used to assess overall
survival (OS) and progression-free-survival (PFS). Statisti-
cal significance was considered for p < 0.05.
Results
144 NSCLC patients were consecutively genotyped in
order to assess 19 single nucleotide polymorphisms
(SNPs). Males were 78.5%. Median age was 61.5 (32 – 89)
years-old. Non-squamous cell histology was 77.1% and
91.4% were stages IIIB and IV. The following SNPs
showed influence in OS: rs2010963 (VEGF + 405 G/C),
p = 0.042, rs3025010 (VEGF intron 5 C/T), p = 0.047,
rs401681 C/T on 5p15, p = 0.046, rs31489 C/A on 5p15,
p = 0.029; and these SNPs showed influence in PFS:
rs9295740 G/A on 6p21, p = 0.074, rs401681 C/T on
5p15, p = 0.021.
Conclusions
This was the first large study in Portugal involving
NSCLC patients and assessment of 19 SNPs on chromo-
some 5p15.33, 6p12, 6p21, 6p21.3, and 15q25. Our study
suggests that variants on chromosome 5p15 and 6p21
are prognostic biomarkers in advanced NSCLC. In the
future, genome-identified patients may improve NSCLC
screening strategies and therapeutic management.
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